Company news
Kura Oncology, Inc. news in 2023
Kura Oncology, Inc.'s news releases, calls and decks from 2023, newest first.
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
December 7, 2023
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
November 27, 2023
Kura Oncology Reports Third Quarter 2023 Financial Results
November 1, 2023
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
November 1, 2023
Kura Oncology to Participate in Three Upcoming Investor Conferences
October 29, 2023
Kura Oncology to Report Third Quarter 2023 Financial Results
October 25, 2023
Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
October 18, 2023
Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
October 16, 2023
Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 3, 2023
Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
September 27, 2023
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
September 18, 2023
Kura Oncology Appoints Brian Powl as Chief Commercial Officer
August 13, 2023
Kura Oncology Reports Second Quarter 2023 Financial Results
August 2, 2023
Kura Oncology to Report Second Quarter 2023 Financial Results
July 26, 2023
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2023
Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2023
Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
June 10, 2023
Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress
May 29, 2023
Kura Oncology to Participate in Two Upcoming Investor Conferences
May 22, 2023
Kura Oncology Reports First Quarter 2023 Financial Results
May 9, 2023
Kura Oncology to Participate in JMP Securities Life Sciences Conference
May 8, 2023
Kura Oncology to Report First Quarter 2023 Financial Results
May 2, 2023
Kura Oncology to Participate in Stifel Targeted Oncology Days
April 17, 2023
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
April 16, 2023
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
March 13, 2023
Kura Oncology to Participate in Upcoming Investor Conferences
February 28, 2023
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
February 8, 2023
Kura Oncology to Participate in SVB Securities Global Biopharma Conference
February 6, 2023
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
January 23, 2023
Calls in 2023
Decks in 2023
- Q3 2023 Earnings Presentation
Earnings · 33 slides · Nov 2, 2023
- 5th RAS-Targeted Drug Development Summit 2023
Conference · 20 slides · September 2023
- EHA Investor Event 2023
Conference · 22 slides · Jun 12, 2023
- Investor Presentation (January 2023)
Investor deck · 34 slides · Jan 9, 2023
- ESMO 2023
Conference · 9 slides · 2023
- EHA 2023 Late-Breaking Presentation
Conference · 14 slides · 2023
- SIE (Italian Hematology Society) 2023 Congress
Conference · 15 slides · 2023